French financial prosecutors have opened a preliminary probe into Sanofi over possible share price manipulation, a person close to the investigation told Reuters. The person close to the investigation confirmed earlier reports from French media La Lettre and news agency AFP, which said a preliminary probe was opened in March and was linked to possible market manipulation caused by the group’s past financial communication, according to Reuters. La Lettre reported the investigation was linked to Sanofi’s communication around the launch of its blockbuster drug Dupixent in 2017. “As a listed company, the financial informations published by Sanofi are accurate, precise and sincere, and are duly audited by two auditing firms,” Sanofi said in an emailed statement to the news agency.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SNY:
- Sanofi price target lowered to EUR 92 from EUR 105 at JPMorgan
- Biotech Alert: Searches spiking for these stocks today
- Ligand acquires Tolerance Therapeutics for $20M in cash
- Sanofi price target lowered to EUR 105 from EUR 115 at Berenberg
- Sanofi price target lowered to EUR 95 from EUR 115 at Barclays